Reproductive factors, exogenous hormone use and risk of hepatocellular carcinoma among US women: Results from the Liver Cancer Pooling Project

British Journal of Cancer

Volumn 112, Issue 7, 2015, Pages 1266-1272

  McGlynn, K A ^a   Sahasrabuddhe, V V ^a   Campbell, P T ^b   Graubard, B I ^a   Chen, J ^a   Schwartz, L M ^a   Petrick, J L ^a   Alavanja, M C ^a   Andreotti, G ^a   Boggs, D A ^c   Buring, J E ^d,e   Chan, A T ^d,f   Freedman, N D ^a   Gapstur, S M ^b   Hollenbeck, A R ^g   Hou, L ^h   King, L Y ^d,f   Koshiol, J ^a   Linet, M ^a   Palmer, J R ^c   Poynter, J N ⁱ   Purdue, M ^a   Robien, K ^j   Schairer, C ^a   Sesso, H D ^d,e   Sigurdson, A ^a   Wactawski Wende, J ^k   Zeleniuch Jacquotte, A ^l   more..

^a NATIONAL CANCER INSTITUTE   (United States)

^b AMERICAN CANCER SOCIETY   (United States)

^c BOSTON UNIVERSITY   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^f HARVARD MEDICAL SCHOOL   (United States)

^g AARP   (United States)

^h NORTHWESTERN UNIVERSITY   (United States)

ⁱ UNIVERSITY OF MINNESOTA   (United States)

^j GEORGE WASHINGTON UNIVERSITY   (United States)

^k UNIVERSITY AT BUFFALO   (United States)

^l NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

more..

Author keywords

Hepatocellular carcinoma; Menopausal hormone therapy; Oophorectomy; Oral contraceptives

Indexed keywords

ESTROGEN; HEPATITIS B SURFACE ANTIGEN; ORAL CONTRACEPTIVE AGENT;

ADULT; AGED; ARTICLE; CANCER RISK; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; ESTROGEN THERAPY; FEMALE; FEMALE FERTILITY; FOLLOW UP; HEPATITIS B; HEPATITIS C; HUMAN; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MENARCHE; MENOPAUSE; MIDDLE AGED; OVARIECTOMY; PRIORITY JOURNAL; PROSPECTIVE STUDY; UNITED STATES; CARCINOMA, HEPATOCELLULAR; LIVER NEOPLASMS; PROPORTIONAL HAZARDS MODEL; REPRODUCTIVE HISTORY;

ADULT; CARCINOMA, HEPATOCELLULAR; COHORT STUDIES; CONTRACEPTIVES, ORAL, HORMONAL; FEMALE; HUMANS; LIVER NEOPLASMS; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; REPRODUCTIVE HISTORY; UNITED STATES;

EID: 84938553508     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2015.58     Document Type: Article

References (38)

1. Cameron R, Imaida K, Ito N (1981) Promotive effects of ethinyl estradiol in hepatocarcinogenesis initiated by diethylnitrosamine in male rats. Gan 72(2): 339-340.
2. Clark JM, Brancati FL, Diehl AM (2002) Nonalcoholic fatty liver disease. Gastroenterology 122(6): 1649-1657.
3. Fernandez E, Gallus S, Bosetti C, Franceschi S, Negri E, La Vecchia C (2003) Hormone replacement therapy and cancer risk: a systematic analysis from a network of case-control studies. Int J Cancer 105(3): 408-412.
4. Fukuda S, Itamoto T, Amano H, Kohashi T, Ohdan H, Tashiro H, Asahara T (2007) Clinicopathologic features of hepatocellular carcinoma patients with compensated cirrhosis surviving more than 10 years after curative hepatectomy. World J Surg 31(2): 345-352.
5. Fwu CW, Chien YC, Kirk GD, Nelson KE, You SL, Kuo HS, Feinleib M, Chen CJ (2009) Hepatitis B virus infection and hepatocellular carcinoma among parous Taiwanese women: nationwide cohort study. J Natl Cancer Inst 101(14): 1019-1027.
6. Gierach GL, Pfeiffer RM, Patel DA, Black A, Schairer C, Gill A, Brinton LA, Sherman ME (2013) Long-term overall and disease-specific mortality associated with benign gynecologic surgery performed at different ages. Menopause 21(6): 592-601.
7. Goldfarb S, Pugh TD (1990) Ovariectomy accelerates the growth of microscopic hepatocellular neoplasms in the mouse: possible association with whole body growth and fat deposition. Cancer Res 50(21): 6779-6782.
8. Henderson BE, Preston-Martin S, Edmondson HA, Peters RL, Pike MC (1983) Hepatocellular carcinoma and oral contraceptives. Br J Cancer 48(3): 437-440.
9. Hsing AW, Hoover RN, McLaughlin JK, Co-Chien HT, Wacholder S, Blot WJ, Fraumeni Jr JF (1992a) Oral contraceptives and primary liver cancer among young women. Cancer Causes Control 3(1): 43-48.
10. Hsing AW, McLaughlin JK, Hoover RN, Co Chien HT, Blot WJ, Fraumeni Jr JF (1992b) Parity and primary liver cancer among young women. J Natl Cancer Inst 84(14): 1118-1119.
11. IARC (1999) Hormonal Contraception and Post-Menopausal Hormonal Therapy. Vol. 72. IARC Press: Lyon, France.
12. Kanaya AM, Herrington D, Vittinghoff E, Lin F, Grady D, Bittner V, Cauley JA, Barrett-Connor E (2003) Glycemic effects of postmenopausal hormone therapy: the Heart and Estrogen/progestin Replacement Study. A randomized, double-blind, placebo-controlled trial. Ann Int Med 138(1): 1-9.
13. Kanazir M, Boricic I, Delic D, Tepavcevic DK, Knezevic A, Jovanovic T, Pekmezovic T (2010) Risk factors for hepatocellular carcinoma: a case-control study in Belgrade (Serbia). Tumori 96(6): 911-917.
14. Kvale G, Heuch I, Nilssen S (1994) Parity in relation to mortality and cancer incidence: a prospective study of Norwegian women. Int J Epidemiol 23(4): 691-699.
15. La Vecchia C, Negri E, Franceschi S, D'Avanzo B (1992) Reproductive factors and the risk of hepatocellular carcinoma in women. Int J Cancer 52(3): 351-354.
16. Lambe M, Trichopoulos D, Hsieh CC, Ekbom A, Pavia M (1993) Parity and hepatocellular carcinoma. A population-based study in Sweden. Int J Cancer 55(5): 745-747.
17. Lobo RA (2007) Surgical menopause and cardiovascular risks. Menopause 14(3 Pt 2): 562-566.
18. Maheshwari S, Sarraj A, Kramer J, El-Serag HB (2007) Oral contraception and the risk of hepatocellular carcinoma. J Hepatol 47(4): 506-513.
19. McGlynn KA, London WT (2011) The global epidemiology of hepatocellular carcinoma: present and future. Clin Liver Dis 15(2): 223-243, vii-x.
20. McKenzie J, Fisher BM, Jaap AJ, Stanley A, Paterson K, Sattar N (2006) Effects of HRT on liver enzyme levels in women with type 2 diabetes: a randomized placebo-controlled trial. Clin Endocrinol 65(1): 40-44.
21. Miller AB, Barclay TH, Choi NW, Grace MG, Wall C, Plante M, Howe GR, Cinader B, Davis FG (1980) A study of cancer, parity and age at first pregnancy. J Chronic Dis 33(10): 595-605.
22. Mucci LA, Kuper HE, Tamimi R, Lagiou P, Spanos E, Trichopoulos D (2001) Age at menarche and age at menopause in relation to hepatocellular carcinoma in women. BJOG 108(3): 291-294.
23. Nakatani T, Roy G, Fujimoto N, Asahara T, Ito A (2001) Sex hormone dependency of diethylnitrosamine-induced liver tumors in mice and chemoprevention by leuprorelin. Jpn J Cancer Res 92(3): 249-256.
24. Naugler WE, Sakurai T, Kim S, Maeda S, Kim K, Elsharkawy AM, Karin M (2007) Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. Science 317(5834): 121-124.
25. Ng IO, Ng M, Fan ST (1997) Better survival in women with resected hepatocellular carcinoma is not related to tumor proliferation or expression of hormone receptors. Am J Gastroenterol 92(8): 1355-1358.
26. Parker WH, Feskanich D, Broder MS, Chang E, Shoupe D, Farquhar CM, Berek JS, Manson JE (2013) Long-term mortality associated with oophorectomy compared with ovarian conservation in the nurses' health study. Obstet Gynecol 121(4): 709-716.
27. Persson I, Yuen J, Bergkvist L, Schairer C (1996) Cancer incidence and mortality in women receiving estrogen and estrogen-progestin replacement therapy-long-term follow-up of a Swedish cohort. Int J Cancer 67(3): 327-332.
28. Plesko I, Preston-Martin S, Day NE, Tzonou A, Dimitrova E, Somogyi J (1985) Parity and cancer risk in Slovakia. Int J Cancer 36(5): 529-533.
29. Shimizu I, Ito S (2007) Protection of estrogens against the progression of chronic liver disease. Hepatol Res 37(4): 239-247.
30. Stanford JL, Thomas DB (1992) Reproductive factors in the etiology of hepatocellular carcinoma. The WHO Collaborative Study of Neoplasia and Steroid Contraceptives. Cancer Causes Control 3(1): 37-42.
31. Tejura S, Rodgers GR, Dunion MH, Parsons MA, Underwood JC, Ingleton PM (1989) Sex-steroid receptors in the diethylnitrosamine model of hepatocarcinogenesis: modifications by gonadal ablation and steroid replacement therapy. J Mol Endocrinol 3(3): 229-237.
32. Tzonou A, Zavitsanos X, Hsieh CC, Trichopoulos D (1992) Liveborn children and risk of hepatocellular carcinoma. Cancer Causes Control 3(2): 171-174.
33. Vesselinovitch SD, Itze L, Mihailovich N, Rao KV (1980) Modifying role of partial hepatectomy and gonadectomy in ethylnitrosourea-induced hepatocarcinogenesis. Cancer Res 40(5): 1538-1542.
34. Wanless IR, Medline A (1982) Role of estrogens as promoters of hepatic neoplasia. Lab Invest 46(3): 313-320.
35. Wu CH, Chan TF, Changchien CC, Yang CY (2011) Parity, age at first birth, and risk of death from liver cancer: evidence from a cohort in Taiwan. J Gastroenterol Hepatol 26(2): 334-339.
36. Yager Jr JD, Yager R (1980) Oral contraceptive steroids as promoters of hepatocarcinogenesis in female Sprague-Dawley rats. Cancer Res 40(10): 3680-3685.
37. Yu MC, Tong MJ, Govindarajan S, Henderson BE (1991) Nonviral risk factors for hepatocellular carcinoma in a low-risk population, the non-Asians of Los Angeles County, California. J Natl Cancer Inst 83(24): 1820-1826.
38. Yu MW, Chang HC, Chang SC, Liaw YF, Lin SM, Liu CJ, Lee SD, Lin CL, Chen PJ, Lin SC, Chen CJ (2003) Role of reproductive factors in hepatocellular carcinoma: impact on hepatitis B- and C-related risk. Hepatology 38(6): 1393-1400.